MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,418K
Net Income
-$20,964K
Net Profit Margin
-1478.42%
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
1,418
10,258
663
5,963
Research and development
17,598
19,238
21,234
15,304
General and administrative
7,601
10,692
7,360
6,427
Total operating expenses
25,199
29,930
28,594
21,731
Income (loss) from operations
-23,781
-19,672
-27,931
-15,768
Interest income
3,157
1,490
1,481
1,592
Other income
18
-7
-5
5
Income (loss) before income taxes
-20,606
-18,189
-26,455
-14,171
Provision for income taxes
60
59
55
58
Net income (loss)
-
-
-28,838*
-
Deemed dividend on warrants
-
-
-750*
-
Net income (loss)
-
-
-
-14,229
Net income (loss) attributable to common stockholders
-20,666
-18,248
-29,589
-
Unrealized gain (loss) on investments, net of tax
-298
-9
-
71
Total comprehensive income (loss)
-20,964
-18,257
-
-14,158
Basic Average Shares
218,939,423
177,273,000
137,935,873*
165,004,291
Diluted Average Shares
218,939,423
177,273,000
137,935,873*
165,004,291
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
income (loss)
-$20,964K
(-17370.00%↓ Y/Y)
Net income (loss)
attributable to common...
-$20,666K
Unrealized gain (loss) on
investments, net of tax
-$298K
(-976.47%↓ Y/Y)
Income (loss) before
income taxes
-$20,606K
(-22543.96%↓ Y/Y)
Provision for income taxes
$60K
(-4.76%↓ Y/Y)
Interest income
$3,157K
(168.00%↑ Y/Y)
Other income
$18K
(5.88%↑ Y/Y)
Income (loss) from
operations
-$23,781K
(-1749.22%↓ Y/Y)
Revenues
$1,418K
(-92.40%↓ Y/Y)
Total operating
expenses
$25,199K
(26.35%↑ Y/Y)
Research and development
$17,598K
(32.10%↑ Y/Y)
General and
administrative
$7,601K
(14.78%↑ Y/Y)
Buy us a coffee
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)